Sickle cell disease in North Europe

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 67, Issue 1, 2007, Pages 27-38

  Howard, J ^a   Davies, S C ^a  

^a CENTRAL MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

Hydroxyurea; Pulmonary hypertension; Screening programmes; Sickle cell disease

Indexed keywords

ADRENALIN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANALGESIC AGENT; ANTIBIOTIC AGENT; CODEINE PHOSPHATE; CYPROTERONE; DIAMORPHINE; ETILEFRINE; FENTANYL; HYDROXYUREA; INFUSION FLUID; MORPHINE; OPIATE; OXYCODONE; SILDENAFIL;

ACUTE CHEST SYNDROME; ANALGESIA; ANAPHYLAXIS; AVASCULAR NECROSIS; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CLINICAL FEATURE; CLINICAL TRIAL; EUROPE; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; HYDRATION; KIDNEY DISEASE; LUNG DISEASE; MIGRATION; NEUROLOGIC DISEASE; NEWBORN ASSESSMENT; PAIN; PAIN ASSESSMENT; PATHOGENESIS; PRENATAL DIAGNOSIS; PRIAPISM; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETINOPATHY; REVIEW; SEDATION; SICKLE CELL ANEMIA; SPLEEN DISEASE; STROKE;

ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; BLOOD TRANSFUSION; CHILD; EUROPE; HUMANS; HYDROXYUREA; INFANT, NEWBORN; NEONATAL SCREENING;

EID: 33846978470     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510601046441     Document Type: Review

References (57)

1. Serjeant GR. Recent advances in sickle cell disease. In: David TJ, editor. Recent advances in paediatrics. Edinburgh: Churchill Livingstone; 1994. pp 141-54.
2. Davies SC, Gilmore A. The role of hydroxyurea in the management of sickle cell disease. Blood Rev 2003;17:99-109.
3. Serjeant GR. Sickle-cell disease. Lancet 1997;350:725-30.
4. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-44.
5. Wierenga KJJ, Hambleton IR, Lewis NA. Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic-based population study. Lancet 2001;357:680-3.
6. Gaston M, Verter JI, Joel I, Woods G, Pegelow C, Kelleher J, et al. Prophylaxis with oral penicillin in children with sickle cell anaemia: a randomized trial. N Engl J Med 1986;314:1594-9.
7. Lees CM, Davies SC, Dezateux C. Neonatal screening for sickle cell disease. The Cochrane Database of Systematic Reviews 2000, Issue 1.
8. Riddington C, Owusu-Ofori S. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. The Cochrane Database of Systematic Reviews 2002 (3):CD003427.
9. Davies GE, Riddington C, Lottenberg R, Dower N. Pneumococcal vaccines for sickle cell disease in children and adults. The Cochrane Database of Systematic Reviews; 2004. p 3.
10. Lee A, Thomas P, Cupidore L, Serjeant B, Serjeant G. Improved survival in homozygous sickle cell disease: lessons from a cohort study. Br Med J 1995;311:1600-2.
11. Zeuner D, Ades AE, Karnon K, Brown J, Dezateux C, Anionwu E. Antenatal and neonatal haemoglobinopathy screening in the UK: review and economic analysis. Health Technol Assess 1999;3.
12. Davies SC, Cronin E, Gill M, Greengross P, Hickman M, Normand C. Screening for sickle cell disease and Thalassaemia: a systematic review with supplementary research (2000). Health Technology Assessment 2000;4.
13. Davies SC, Oni L. Management of patients with sickle cell disease. Br Med J 1997;315:656-60.
14. Rees DC, Olujohengbe AD, Parker NE, Stephens AD, Telfer P, Wright J. Guidelines for the management of the acute painful crisis in sickle cell disease. Br J Haematol 2003;120:744-52.
15. Benjamin LJ, Swinson GI, Nagel RI. Sickle cell anaemia day hospital: an approach for the management of uncomplicated painful crises. Blood 2000;95:1130-6.
16. Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, et al. Cerebrovascular disease in sickle cell disease: rates and risk factors. Blood 1998;91:288-94.
17. Charache S, Terrin ML, Moore RD, Dover GJ, Benton FB, Wadawiw M, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anaemia. N Engl J Med 1995;332:1317-22.
18. Pegelow CH, Adams RJ, McKie V, Abboud M, Berman B, Miller ST. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr 1995;126:869-9.
19. Wang WC, Kovnar EH, Tonkin IL, Mulhern RK, Langston JW, Day SW, et al. High risk of recurrent stroke after discontinuation of five to twelve years of transfusion therapy in patients with sickle cell disease. J Pediatr 1991;118:377-82.
20. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, et al. Prevention of a first stroke by transfusions in children with sickle cell anaemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998;339:5-11.
21. Miller ST, Macklin EA, Pegelow CH, Kinnay TR, Sleeper LA, Bellow A, et al. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease, 2001;139:385-90.
22. Charache S, Scott JC, Charache P. Acute chest syndrome in adults with sickle cell anaemia. Arch Intern Med 1979;138:67-9.
23. Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, Dean D, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med 2000;342:1855-65.
24. Emre U, Miller St, Gutieriez M, Steiner P, Rao SP, Rao M. Effect of transfusion in acute chest syndrome of sickle cell disease. J Pediatr 1995;127:901-4.
25. Bellet PS, Kalinyak KA, Shukla R, Gelfand M, Rucknagel DL. Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases. N Engl J Med 1995;333:699-703.
26. Knight-Madden JM, Hambleton IR. Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease. The Cochrane Database of Systematic Reviews 2003, Issue 3. Art. no. CD 003733. DOI: 10.1002/14651858.
27. Charache S, Lubin B, Reid CD. Stroke. In: Charache S, Lubin B, Reid CD, editors. Management and therapy of sickle cell disease, 3rd edn. Washington, DC: US Department of Health; 1995. pp 53-8.
28. Powars D, Weidman JA, Odom-Maryon T, Niland JC, Johnson C. Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure. Medicine 1988;67:66-76.
29. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004;350:886-95.
30. Machado RF, Gladwin MT. Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension. Br J Haematol 2005;129:449-64.
31. Machado RF, Martyr S, Kato GJ, Barst RJ, Anthi A, Robinson MR, et al. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol 2005.
32. Mantadakis E, Ewalt DH, Cavender JD, Rogers ZR, Buchanan GR. Outpatient penile aspiration and epinephrine irrigation for young patients with sickle cell anaemia and prolonged priapism. Blood 2000;95:78-82.
33. Gbadoe AD, Atakouma Y, Kusiaku K, Assimadi JK. Management of sickle cell priapism with etilefrine. Arch Dis Child 2001;85:52-3.
34. Ware HE, Brooks AP, Toye R, Berney SI. Sickle cell disease and silent avascular necrosis of the hip. J Bone Joint Surg 1991;73:947-49.
35. Powars DR, Hiti A, Ramicone E, Johnson C, Chan L. Outcome in hemoglobin SC disease: a four-decade observational study of clinical, hematologic and genetic factors. Am J Hematol 2002;70:206-15.
36. Claster S, Vichinsky EP. Managing sickle cell disease. B Med J 2003;327:1151-5.
37. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutler A, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anaemia: risks and benefits of up to 9 years of treatment. J Am Med Assoc 2003;289:1645-51.
38. Ferster A, Vermylen C, Cornu G, Buyse M, Corazza F, Devalck C, et al. Hydroxyurea for treatment of severe sickle cell anaemia: a pediatric clinical trial. Blood 1996;88:1960-4.
39. Ferster A, Tahriri P, Vermylen C, Sturbis G, Corazza F, Fondu P, et al. Five years of experience with hydroxyurea in children and adults with sickle cell disease. Blood 2001;97:3628-32.
40. Diav-Citrin O, Hunnisett L, Sher GD, Koren G. Hydroxyurea use during pregnancy: case report in sickle cell disease and review of the literature. Am J Hematol 1999;60:148-50.
41. Horiuchi K, Golden JA, Das SK, Scully M, Lian L, Ohene-Frempong K, et al. Adverse effects of hydroxyurea on growth and development of young mice. Blood 1998;92 Suppl 1:160a.
42. Hankins JS, Ware RE, Rogers ZR, Wynn LW, Lane PA, Scott JP, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood 2005.
43. Miller DM, Winslow RM, Klein HG, Wilson KC, Brown FL, Statham NJ. Improved exercise performance after exchange transfusion in subjects with sickle cell anaemia. Blood 1980;56:1127-31.
44. Riddington C, Williamson L. Preoperative blood transfusions for sickle cell disease. The Cochrane Database of Systematic Reviews 2004:CD003149- CD00493X.
45. Davies SC, McWilliam AC, Hewitt PE, Devenish A, Brozovic M. Red cell alloimmunization in sickle cell disease. Br J Haematol 1986;63:241-5.
46. Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin B. Alloimmunization in sickle cell anaemia and transfusion of racially unmatched blood. N Engl J Med 1990;322:1617-21.
47. Rosse WF, Gallagher D, Kinney, Castro O, Dosik H, Moohr J, et al. Transfusion and alloimmunization in sickle cell disease: The Cooperative Study of Sickle Cell Disease. Blood 1990;76:1431-7.
48. Cullis JO, Win N, Dudley JM, Kaye T. Post-transfusion hyperhaemolysis in a patient with sickle cell disease: use of steroids and intravenous immunoglobulin to prevent further red cell destruction. Vox Sang 1995;69:355-7.
49. Koshy M, Burd L, Wallace D, Moawad A, Baron J. Prophylactic red cell transfusions in patients with sickle cell disease: a randomized cooperative study. N Engl J Med 1998;319:1447-52.
50. Vichinsky EP, Haberkan CM, Neumayr L, Earles AN, Black D, Koshy M, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. N Engl J Med 1995;333:206-13.
51. Hatley RM, Christ D, Howell CF, Herline AJ, Gadacz TR. Laparoscopic cholecystectomy in children with sickle cell disease. Am Surg 1995;61:169-71.
52. Roberts-Harewood M, Nokes TJC, Taylor PC, Davies SC. Adenotonsillectomy in sickle cell disease: is routine transfusion necessary? Br J Haematol 1997;97 Suppl 1:75.
53. Johnson FL, Look AT, Gockerman J, Ruggiero MR, Dalla-Pozza L, Billings FT 3rd. Bone marrow transplantation in a patient with sickle cell anaemia. N Engl J Med 1984;311:780-3.
54. Hoppe CC, Walters MC. Bone marrow transplantation in sickle cell anaemia. Curr Opin Oncol 2001;13:85-90.
55. Bernaudin F, Souillet G, Vannier JP, Vilmer E, Michel G, Lutz P, et al. Report of the French experience concerning 26 children transplanted for severe sickle cell disease. Bone Marrow Transpl 1997;19 Suppl 2:112.
56. Vermylen C, Cornu G, Ferster A, Brichard B, Ninane J, Ferrant A. Haematopoietic stem cell transplantaion for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transpl 1998;22:1-16.
57. Walters MC, Storb R, Patience M, Leisenring W, Taylor T, Sanders JE, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Blood 2000;95:1918-24.